AdComMay 26, 2026
FDA advisory — Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine▸
high impact
ReadoutMay 16, 2026
Clinical data — Assessing Moderna (MRNA) Valuation After Flu Vaccine Trial Success And Hantavirus Research Attention▸
medium impact
Data +May 13, 2026
Positive data — Moderna (MRNA) Shares Skyrocket, What You Need To Know▸
high impact
DealMay 12, 2026
Deal — 5 Insightful Analyst Questions From Moderna’s Q1 Earnings Call▸
medium impact
Data +May 08, 2026
Positive data — Moderna Flu Breakthrough And Hantavirus Push Reframe Long Term Story▸
high impact
EarningsMay 01, 2026
Q1 2026 report+7.5%positive
AdComMay 01, 2026
FDA advisory — Moderna Q1 Earnings: Revenue Beat Overshadowed By Litigation Charge, Pipeline Drives Outlook▸
high impact
Data +May 01, 2026
Positive data — Moderna (NASDAQ:MRNA) Beats Expectations in Strong Q1 CY2026, Stock Soars▸
high impact
DealMay 01, 2026
Deal — Moderna (MRNA) Q1 2026 Earnings Transcript▸
medium impact
FilingApr 29, 2026
Regulatory filing — Moderna (MRNA): 10 Best Performing S&P 500 Stocks So Far in 2026▸
medium impact
ReadoutApr 21, 2026
Clinical data — Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting▸
medium impact
EarningsFeb 13, 2026
FY 2025 report+17.7%positive
EarningsJan 12, 2026
FY 2025 report+16.3%positive
EarningsNov 06, 2025
Q3 2025 report+8.5%positive
EarningsAug 01, 2025
Q2 2025 report-3.2%negative
Data +Jul 10, 2025
mRNA-4157 Phase 3 interim (melanoma)▸
high impact
EarningsMay 01, 2025
Q1 2025 report-9.6%negative
EarningsFeb 14, 2025
FY 2024 report+2.2%muted
EarningsJan 13, 2025
FY 2024 report-4.0%negative
EarningsNov 07, 2024
Q3 2024 report-13.5%negative
Data +Sep 10, 2024
mRNA-4157 Phase 2b melanoma 3-year follow-up▸
high impact
EarningsAug 01, 2024
Q2 2024 report-12.6%negative